Additional targets have been shown to be associated with anxiety disorders, for example, psilocybin, a drug with therapeutic potential for anxiety, which reduces the expression of prostaglandin-endoperoxide synthase 2 (PTGS2) in the hippocampus [50]. This evidence concerns the gene PTGS2 and anxiety disorder.